Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short-term Investments (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Short-term Investments for 12 consecutive years, with $23.7 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed 0.41% to $23.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.7 million through Dec 2025, changed 0.41% year-over-year, with the annual reading at $23.7 million for FY2025, 0.41% changed from the prior year.
  • Short-term Investments for Q4 2025 was $23.7 million at Anika Therapeutics, up from $22.2 million in the prior quarter.
  • The five-year high for Short-term Investments was $36.7 million in Q2 2023, with the low at $22.0 million in Q1 2025.
  • Average Short-term Investments over 5 years is $29.3 million, with a median of $29.8 million recorded in 2021.
  • The sharpest move saw Short-term Investments skyrocketed 1093.24% in 2021, then plummeted 31.46% in 2025.
  • Over 5 years, Short-term Investments stood at $29.8 million in 2021, then rose by 16.03% to $34.6 million in 2022, then fell by 23.87% to $26.4 million in 2023, then decreased by 10.49% to $23.6 million in 2024, then grew by 0.41% to $23.7 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $23.7 million, $22.2 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.